OSI-027

TargetMol
Product Code: TAR-T6319
Supplier: TargetMol
CodeSizePrice
TAR-T6319-1mg1mg£99.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6319-2mg2mg£109.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6319-5mg5mg£133.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6319-1mL1 mL * 10 mM (in DMSO)£136.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6319-10mg10mg£184.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6319-25mg25mg£280.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6319-50mg50mg£399.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6319-100mg100mg£549.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
OSI-027 is a selective and potent dual inhibitor of mTORC1 and mTORC2 with IC50 of 22 nM and 65 nM, and more than 100-fold selectivity observed for mTOR than PI3Kα, PI3Kβ, PI3Kγ or DNA-PK. Phase 1.
CAS:
936890-98-1
Formula:
C21H22N6O3
Molecular Weight:
406.446
Pathway:
DNA Damage/DNA Repair; PI3K/Akt/mTOR signaling; Autophagy
Purity:
0.98
SMILES:
COc1cccc2cc([nH]c12)-c1nc([C@H]2CC[C@@H](CC2)C(O)=O)n2ncnc(N)c12
Target:
DNA-PK; PI3K; mTOR; Autophagy

References

Sun C Y, Li Y Z, Cao D, et al. Rapamycin and trametinib: a rational combination for treatment of NSCLC. International Journal of Biological Sciences. 2021, 17(12): 3211-3223. Altman JK, et al. Clin Cancer Res, 2011, 17(13), 4378-4388. Bhagwat SV, et al. Mol Cancer Ther. 2011, 10(8), 1394-1406. Li H, et al. Breast Cancer Res Treat, 2012, 134(3), 1057-1066. Zhi X, et al. OSI-027 modulates acute graft-versus-host disease after liver transplantation in a rat model. Liver Transpl. 2017 Sep;23(9):1186-1198. Falcon BL, et al. Cancer Res, 2011, 71(5), 1573-1583.